Introduction: Anterior and posterior segment eye diseases are highly challenging to treat, due to the barrier properties and relative inaccessibility of the ocular tissues.
• Drug delivery to the eye is challenging due to the extremely delicate nature, relative inaccessibility, and barrier properties of ocular tissues
• Topical and systemic routes of ocular drug delivery result in low or subtherapeutic drug levels; drug delivery implants need surgical implantation.
• Injections into the eye using conventional hypodermic can provide direct access to the target tissues. However, this method is highly invasive and causes considerable discomfort, pain and associated with a number of side effects • Microneedles (MNs) could offer minimally-invasive means of ocular drug delivery, less tissue trauma, less drug dosage and precise localisation of the medication.
• MNs allow precise injections within the thin ocular tissues (e.g. sclera and cornea) -an advantage for localized drug delivery In general, conditions that affect the anterior chamber are less likely to be sight threatening compared to those that affect the posterior segment. Nevertheless, drug delivery to the eye can be challenging, owing to the extremely delicate nature of the ocular tissues concerned, their relative inaccessibility, and barrier properties of ocular tissues [3, 4] , which hinders efficient drug diffusion to target tissues. For example, posterior segment of the eye, which includes the retina, choroid, and vitreous body, is difficult to access due to the recessed location within the orbital cavity.
To date, multiple approaches have been used to deliver drugs to the eye such as systemic, topical, periocular (or transscleral) and intravitreal routes. Topical (e.g. eye drops) and systemic (e.g. oral tablets) routes result in low or sub-therapeutic drug levels due to multiple ocular barriers, requiring administration of unnecessarily high concentrations of drug that causes drug-related toxicity and producing low treatment efficacy [5] . To overcome the barrier function of the eye and to enhance localization of the drug close to the target tissues, injections are given either directly into the eye (intravitreal injection, IVT), around the outer surface of the eye (periocular or transscleral route) or within the tissues (intracorneal and intrascleral). These injections are given using conventional hypodermic needles. Although periocular route is considered to be less invasive than the IVT, transient diffusion of a drug across the sclera is limited. Drug diffusion across the scleral membrane is dependent upon drug's solubility, molecular weight/molecular radius, charge and polarity [6] . However, this method has shown low intraocular bioavailability due to a delay in diffusion through the sclera, systemic clearance and loss of drug before reaching the target tissues (e.g. retina) [7] . One of the standard treatments to overcome limitations of periocular injections is either an IVT, for posterior segment diseases, or intracorneal injections, for anterior segment diseases.
Using conventional hypodermic needles for intraocular injections is known to causes considerable discomfort, pain and requires a specialized set of skills. Notably, traditional injections given on frequent basis and over long-term may increase the chances of severe ocular complications and poor patient compliance. Therefore, there is a high demand for less invasive technologies that not only enhance patient compliance but also allow localised and precise drug delivery to the eye. In this regard, application of minimally-invasive microneedles (MNs) for ocular drug delivery is a relatively new concept. To date, only limited work has been done in this area. Therefore, this review article seeks to provide an overview of -typical challenges that are often faced to achieve efficient ocular drug levels within targeted tissue(s) of the eye; problems encountered using conventional hypodermic needlebased ocular injections; and how minimally-invasive MNs could assist in overcoming these challenges in treating sight-threatening eye diseases. It also provides an overview of the limitations and difficulties of MNs application to the eye and its prospects. Furthermore, to the author's knowledge, this is the first review of MNs application for ocular drug delivery, which is aimed to benefit researchers in this field.
Challenges and Obstacles of Ocular Drug Delivery
Although eye offers a convenient site for drug administration for various conditions, there are many challenges. Drug delivery research has significantly increased for other routes such as oral and transdermal routes, whereas progress in the area of ocular drug delivery has been gradual and relatively limited. Lee and Robinson in 1986 described the majority of ocular drug delivery systems as 'primitive and inefficient' [9], referring mainly to solutions, suspensions, and ointments. In 1995 around 90% of the ophthalmic formulations on the market were based on these three systems [10] . This statement can still be employed to describe a large number of systems currently used for the treatment of ocular conditions, although substantial advances have been made to enable targeting of ocular tissues in recent years, and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Many researchers attest to the difficulties of effective and efficient drug delivery to the eye, primarily due to the range of ocular barriers that are crucial in maintaining healthy physiological function but pose a variety of challenges for drug delivery.
Following sections briefly, discuss the challenges faced and need for invasive procedures to overcome the barrier function of ocular tissues.
Anterior Barriers
In the anterior segment of the eye, the first challenge to drug delivery is the precorneal lacrimal fluid. Lacrimal fluid turnover and clearance is approx. 1 µL/min
[12] via the nasolacrimal duct. Therefore, formulations instilled to the eye are cleared from the ocular surface in a matter of minutes [13] . Additionally, the lacrimal fluid is rich in peptides and proteins, which are capable of binding drug molecules and inhibiting their release or permeation [14] .
The next barrier encountered in the anterior segment is the cornea. The cornea is the clear, outer layer of the eyeball, with dual action of limiting the entry of exogenous substances into the eye and protecting the ocular tissue. This tissue in an adult human has an average dimension of 11.5 mm horizontally, 10.5 mm vertically with an mean surface area of 1.3 cm 2 , representing around 7% of the total surface area of an eyeball.
The thickness in the central region is around 0.52 mm and increases towards the periphery [15] . Cornea is a multi-layered tissue composed of five distinct layers; from anterior to posterior they are the epithelium, Bowman's layer, stroma, Descemet's membrane, and endothelium, which affect the transport of drug molecules into the eye.
The epithelium layer with an approximately of 50 µm in thickness consists of 5-7 layers of superficial, wing and basal epithelial cells. This layer forms a significant barrier to topical ophthalmic formulations, especially for hydrophilic and macromolecular drugs due to the barriers lipoidal nature and the tight junctions between the cells, importantly in the superficial epithelium cells [17, 18] . Drug molecules require a partition coefficient of greater than 1 to adequately permeate the epithelium [19] . The molecular weight of hydrophilic molecules also plays a major factor in their permeation through the corneal epithelium [20] with those larger than 60-100 Da being unable to pass [20, 21] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Posterior Barriers
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Ocular injections to overcome barrier functions
Regarding ocular drug delivery, the choice of route of administration or type of delivery system is very much dictated by the target tissue and potential barriers that need to overcome. Table 1 summarises different routes of ocular drug delivery along with their benefits and challenges. As can be appreciated from the information provided in Table 1 , each route and method of administration have its advantages and disadvantages. However, this review is primarily focused on minimally-invasive means of ocular drug delivery using MNs. Hence, we will discuss challenges that are faced using highly-invasive conventional hypodermic injections in delivering drugs to the eye ( Fig. 1 ). Hypodermic needle-based injections are clinically employed to gain direct access to the target tissues to overcome barrier function of the eye, in treating a number of diseases.
Anterior segment injections
Topical administration of eye drops has very low ocular bioavailability (< 5%).
Therefore, frequent drops are necessary, yet it is only effective in treating diseases of the front of the eye. Whereas, due to biological barriers, the systemic administration has to be given at very high doses which cause systemic toxicity.
Therapies used to treat diseases of the anterior segment of the eye have been widely researched and are well documented. Formulation approaches for treating anterior eye diseases include eye drops, gels, suspensions, and emulsions, to name a few. However, the most commonly formulated preparation is topical eye drops that have the advantage of being non-invasive and can be easily self-administered, resulting in good patient compliance. Nevertheless, topical administration is inefficient due to the barrier properties of corneal epithelium, thus requiring either frequent administration of medication or high doses -especially in treating certain corneal conditions such as CNZ, dystrophy, fungal and bacterial keratitis, which may lead to vision impairment or loss if not treated effectively [38] . As a result, direct injections of medication are commonly practised in treating these conditions such as subconjunctival, intrastromal, intracameral, or intracorneal injections ( Fig. 1 ). These injections enable achieving high drug concentrations within the specific tissue of the anterior segment of the eye, and found to be particularly beneficial in the emergency management of acute conditions (e.g. CNZ and fungal keratitis).
In subconjunctival injections, selected medication is directly delivered in subconjunctival space ( Fig. 1 ). It is considered to be most patient friendly than any other types of ocular injections. Most commonly hypodermic needles of sizes ranging from 21-30G are used for subconjunctival injections, with injections volumes of up to 0.1 ml. For example, in treating CNZ, bevacizumab (Avastin ® ) was administered by topical route, at a concentration of 2.5 mg/ml eye drop (10 µL) given 5-times per day
[39], but higher concentration (4, 5 or 10 mg/ ml) eye drops were given only 2-times per day. Here, a frequent administration is required due to poor penetration of the bevacizumab, which is a high molecular weight (149kDa) hydrophilic drug.
Alternatively, to lower drug concentrations and reduce the frequency of administration, subconjunctival injections were given at 1.25 mg or 2.5mg/0. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 
Posterior segment Injections
Delivery of drug molecules, to treat visually impairing ocular conditions that originate in the posterior segment of the eye, has been the most challenging task to the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 Drug formulations can also be injected on the outer surface of the eyeball, through periocular injections (transscleral delivery) such as sub-tenon, retrobulbar, peribulbar and posterior juxtascleral ( Fig. 1 ), which are considered to be less invasive than IVT.
Transscleral delivery via periocular administration is thought to be one of the safest means of achieving stable drug concentrations within the vitreous and retina, although there have been reports of anterior segment complications after periocular injection such as raised IOP, cataract, and strabismus. Other challenges to drug delivery via the transscleral are dependent on the nature of the drug molecule. Interestingly, the sclera is highly permeable to large drug molecules; however the RPE is a significant barrier to diffusion for both these macromolecules and hydrophilic drug molecules, it may be the rate-limiting feature in the delivery of these molecules via the transsceleal route to the retina [60] . While molecular weight isn't a major factor in drug delivery via the transscleral route, molecular radius of the drug molecule is. It has been shown that a smaller molecular radius will result in increased permeability through the scleral tissue [30] . • A 'coat and poke' strategy that relies on coating a drug formulation onto the MNs and subsequent insertion of the coated MN array into the tissue. The drug is deposited within the tissue by the dissolution of the coating.
• The third mode of drug delivery via MNs utilizes incorporation of drug molecules into the structure of polymeric MNs and subsequent insertion into the skin. The drug delivery depends on the rate of polymer dissolution or degradation within the skin.
• Drug molecules can also be transported across the tissue via injection through hollow MNs, which is similar to the application of hypodermic needles [67].
• Swelling MNs fabricated using polymers have been developed more recently.
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The fundamental advantage of using MNs is its ability for painless or minimallyinvasive nature due to its micron-sized dimensions. However, in this study the term microneedle perhaps needs reconsideration, as the MNs were surgically implanted and were much higher in dimensions than those employed in both ocular and transdermal application. In fact, upon HMN injection the gel turned into a semi-solid implant and effectively encapsulated within the sclera to form an intrascleral implant, as seen in the Fig. 5c . Such methods of implant formation, without the need for surgical intervention, would aid or enhance patient acceptability, and at the same time overcome a number of side effects that are commonly seen with surgical administration.
Conclusion
Ocular drug delivery is gaining significant interest among academia and precision, accuracy and reproducibility; and manufacturing costs. Finally, MNs has significant potential to offer combined benefit of being minimally-invasive in application and ability to provide sustained localised drug delivery, which will provide significant benefits in overcoming current challenges faced by frequent intraocular injections using hypodermic needles. Besides, precise anterior segment injections in cornea and sclera, often less than 1000 µm in thickness, using long hypodermic needles is extremely challenging. Use of hypodermic needles is associated with higher degree of tissue trauma. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 Contrary to the solid silicon MNs, hollow glass MNs are intrinsically brittle and can be broken off accidently which can be a cause of concern. Moreover, it has been demonstrated that the hollow MN cannot deliver drug solution without retraction of MN from the sclera at a predetermined rate (e.g. 60 µm increments every 3 min) and
to a certain critical distance (around 300 µm). Infusion of drug formulation through the hollow MN also requires certain pressure, which is dependent upon viscosity and geometric properties of the MN and viscoelastic properties of the ocular tissue.
Uncontrolled retraction from the sclera could lead complete removal of the MN and leakage of the drug onto the sclera surface affecting the amount of drug delivered into the sclera. Thus, special insertion devices and infusion system are required so as to enable MN-based injections in a controlled manner. On the other hand, use of tissue solubilising enzymes (hyaluronidase) can aid the creation of additional space -to accommodate the drug formulation at the target location, but both short-term and long-term effects of tissue integrity must be taken into considered.
Unlike steel or glass MNs, biocompatible and biodegradable polymeric materials can be used in fabrication of MNs. Polymeric MNs will have the advantage of either being completely soluble within the ocular tissue or remain as a depot for long-term drug delivery. And, due to the same reason, the disposable of polymeric MNs will be less of an issue unlike metal/glass MNs, that will have to perhaps follow similar guidelines to that of hypodermic needles.
Other factors to consider are MNs sterility and mechanical properties. For example, it could be easy and cost-effective to have MNs, that are made form steal or glass, to sterilise in similar fashion to that of hypodermic needles. However, polymeric MNs needs special considerations due to their stability issues to heat and other forms of sterilisation; therefore, may need sterile manufacturing. MNs mechanical strength is also a key for its effective application -e.g. metal or glass MNs can withstand higher forces of application than soluble or polymeric-based MNs. Therefore, it is important to consider factors such as type and design of MNs, type of ocular tissues and forces required, so as to enable us to develop MNs of desired qualities. Application of MNs to the eye is another challenge to be addressed, although it is not as straight forward 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 Finally, MNs has the potential to revolutionise ocular drug delivery, as it achieved with transdermal drug delivery. However, this will be highly depended upon the translation of its benefits from lab to the clinic, since to date only one clinical trial is ongoing in this area.
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